Audere Capital

Audere Capital is a New York City seed-stage VC backing companies under a societal resilience thesis, with stated focus areas in artificial intelligence, robotics and automation, advanced manufacturing, next-generation communications, and cybersecurity. The fund sits in the resilience and defense-tech-adjacent category rather than the digital health category. The source record flags the firm as not healthcare-relevant and lists no disclosed healthcare sub-vertical exposure.

The relevance for healthcare-tangent founders is narrow but plausible where the resilience thesis overlaps with biosecurity, pandemic preparedness, autonomous medical logistics, ruggedized clinical communications and connectivity, manufacturing of medical countermeasures, and cybersecurity for healthcare critical infrastructure. Founders working on those crossover areas may find a credible thesis fit, particularly where dual-use defense and healthcare buyers both exist. Portfolio companies are not disclosed in the input record. Founders pitching pure clinical AI, EHR-adjacent tools, physician workflow software, or payer-direct products will not find a fit and should target healthcare-dedicated investors instead.

Disclosed check size is $1M to $5M, with seed-stage focus and United States geographic scope. The fund’s stated transaction types are lead and co-invest, which means it can anchor a seed round when the thesis fit is strong. Underwriting weighs strategic value of the technology to national resilience alongside commercial dynamics, so founders should be ready to engage on the resilience and dual-use frame rather than on a pure commercial story.

Named team members are not provided in the input record. The firm’s team page is the right reference for partner identification before outreach.

Approach Audere Capital only when your company sits credibly within the resilience thesis, with a real connection to biosecurity, healthcare critical infrastructure, medical countermeasures manufacturing, or dual-use defense-and-healthcare technology. Pure commercial physician AI, EHR software, hospital workflow automation, billing and revenue cycle, and consumer wellness founders are out of scope and should redirect outreach to healthcare-dedicated funds elsewhere in this directory. The right entry, if a fit exists, is a warm introduction from a defense-tech advisor, a national-security-adjacent operator, or a fellow seed fund familiar with the resilience thesis. When pitching, lead with the resilience mission, the dual-use customer pathway, and the technology primitive, because that ordering matches the fund’s thesis. Vertical healthcare-only founders should target dedicated healthcare investors and treat Audere as out of scope.